@article{0a5824e02a87429f8e17cc3575b4834b,
title = "Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder",
abstract = "Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.",
keywords = "Cognitive function, Major depression, One-carbon cycle, Pharmacotherapy, S-adenosylmethionine",
author = "Y. Levkovitz and Alpert, {J. E.} and Brintz, {C. E.} and D. Mischoulon and Papakostas, {G. I.}",
note = "Funding Information: J.E.A. has received research support from: Abbott Laboratories, Alkermes, Lichtwer Pharma GmbH, Lorex Pharmaceuticals; Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb Company, Cephalon, Cyberonics, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, J & J Pharmaceuticals, Novartis, Organon Inc., PamLab, LLC, Pfizer Inc., Pharmavite, Roche, Sanofi/Synthelabo, Solvay Pharmaceuticals, Inc., and Wyeth-Ayerst Laboratories. He has participated on advisory boards for or consulted to: Eli Lilly & Company, Pamlab LLC, and Pharmavite LLC. He has received speakers{\textquoteright} honoraria from: Eli Lilly & Company, Janssen, Organon, Reed Medical Education. He has no relevant equity holdings, patents or royalties. Funding Information: D.M. has received support from the following companies during the past 3 years. He has research support (usually as donated medications for clinical trials) from Laxdale (Amarin), Nordic Naturals, Ganeden, SwissMedica. He has participated on advisory boards for or consulted to Bristol-Meyers Squibb Company, PamLab. He has received speakers{\textquoteright} honoraria from Pamlab, Virbac; Nordic Naturals. He has received support from Pamlab for writing. He has no relevant equity holdings. He has patents/royalties from Back Bay Scientific for PMS Escape (patent application pending). He receives receive honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supporting programs along with participant tuition. Commercial entities currently supporting the MGH Psychiatry Academy are listed on the Academy's website http://www.mghcme.org . No payment from any individual entity or company has exceeded $10,000 per year. ",
year = "2012",
month = oct,
doi = "10.1016/j.eurpsy.2011.03.006",
language = "English (US)",
volume = "27",
pages = "518--521",
journal = "Psychiatrie et Psychobiologie",
issn = "0924-9338",
publisher = "Elsevier Masson",
number = "7",
}